PURPOSE: Inflammation may play a role in the development and progression of many cancers, including prostate cancer. We sought to test whether histological inflammation within prostate cancer was associated with more aggressive disease. METHODS: The slides of prostatectomy specimens were reviewed by a board-certified pathologist on 287 men from a Veterans Affairs Medical Center treated with radical prostatectomy from 1992 to 2004. The area with the greatest tumor burden was scored in a blinded manner for the degree of inflammation: absent, mild, or marked. We used logistic and Cox proportional hazards regression analysis to examine whether categorically coded inflammation score was associated with adverse pathology and biochemical progression, respectively. RESULTS: No inflammation was found in 49 men (17%), while 153 (53%) and 85 (30%) had mild and marked inflammation. During a median follow-up of 77 months, biochemical recurrence occurred among 126 (44%) men. On multivariate analysis, more inflammation was associated with greater risk of positive margins, capsular penetration, and seminal vesicle invasion (all p < 0.05). Marked inflammation was associated with increased PSA recurrence risk when adjusting for preoperative features only (HR 2.08, 95% CI 1.02-4.24), but not after adjusting for pathologic features. CONCLUSIONS: Inflammation within prostate cancer was associated with more advanced disease, although it is unclear whether aggressive disease caused increased inflammation or inflammation caused aggressive disease.
PURPOSE:Inflammation may play a role in the development and progression of many cancers, including prostate cancer. We sought to test whether histological inflammation within prostate cancer was associated with more aggressive disease. METHODS: The slides of prostatectomy specimens were reviewed by a board-certified pathologist on 287 men from a Veterans Affairs Medical Center treated with radical prostatectomy from 1992 to 2004. The area with the greatest tumor burden was scored in a blinded manner for the degree of inflammation: absent, mild, or marked. We used logistic and Cox proportional hazards regression analysis to examine whether categorically coded inflammation score was associated with adverse pathology and biochemical progression, respectively. RESULTS: No inflammation was found in 49 men (17%), while 153 (53%) and 85 (30%) had mild and marked inflammation. During a median follow-up of 77 months, biochemical recurrence occurred among 126 (44%) men. On multivariate analysis, more inflammation was associated with greater risk of positive margins, capsular penetration, and seminal vesicle invasion (all p < 0.05). Marked inflammation was associated with increased PSA recurrence risk when adjusting for preoperative features only (HR 2.08, 95% CI 1.02-4.24), but not after adjusting for pathologic features. CONCLUSIONS:Inflammation within prostate cancer was associated with more advanced disease, although it is unclear whether aggressive disease caused increased inflammation or inflammation caused aggressive disease.
Authors: Salaheddin M Mahmud; Simon Tanguay; Louis R Bégin; Eduardo L Franco; Armen G Aprikian Journal: Eur J Cancer Prev Date: 2006-04 Impact factor: 2.497
Authors: Michael F Leitzmann; Meir J Stampfer; Jing Ma; June M Chan; Graham A Colditz; Walter C Willett; Edward Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-10 Impact factor: 4.254
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Alan W Partin Journal: J Urol Date: 2006-10 Impact factor: 7.450
Authors: Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich Journal: Cancer Date: 2009-08-15 Impact factor: 6.860
Authors: David A Cavazos; Matthew J deGraffenried; Shruti A Apte; Laura W Bowers; Kaitlin A Whelan; Linda A deGraffenried Journal: Nutr Cancer Date: 2014-09-29 Impact factor: 2.900
Authors: Yiwen Zhang; Cindy Ke Zhou; Michelangelo Fiorentino; Ericka M Ebot; Emily M Rencsok; Katja Fall; Tamara L Lotan; Massimo Loda; Francesca Giunchi; Elizabeth A Platz; Angelo M De Marzo; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-09-18 Impact factor: 4.254
Authors: Cheryl Jacobs Smith; Tiffany H Dorsey; Wei Tang; Symone V Jordan; Christopher A Loffredo; Stefan Ambs Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-03-14 Impact factor: 4.254
Authors: Ilir Agalliu; Steve Williams; Brandon Adler; Lagu Androga; Michael Siev; Juan Lin; Xiaonan Xue; Gloria Huang; Howard D Strickler; Reza Ghavamian Journal: Cancer Causes Control Date: 2015-03-14 Impact factor: 2.506
Authors: Frank J Jenkins; Tsion Z Minas; Wei Tang; Tiffany H Dorsey; Stefan Ambs Journal: Prostate Cancer Prostatic Dis Date: 2022-04-25 Impact factor: 5.554
Authors: Marvin E Langston; Karen S Sfanos; Saira Khan; Trang Q Nguyen; Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-02 Impact factor: 4.090
Authors: Maeve Kiely; Ginger L Milne; Tsion Z Minas; Tiffany H Dorsey; Wei Tang; Cheryl J Smith; Francine Baker; Christopher A Loffredo; Clayton Yates; Michael B Cook; Stefan Ambs Journal: J Natl Cancer Inst Date: 2022-01-11 Impact factor: 13.506